telix pharmaceuticals

Latest news and analysis on telix pharmaceuticals

Equities

The ASX's hottest company has gone from zero revenue to $1.2 billion in 4 years

This business is up more than 20-fold in 5 years, with brokers and fund managers lining up to call it a buy.
APT
PME
Tom Richardson
Livewire Markets
Reporting Season

Inaugural profit overlooked as R&D spending soars at Telix Pharmaceuticals

Telix Pharmaceuticals has just reported its first year of positive operating cashflow... helping it to achieve NPAT.
Ally Selby
Livewire Markets
2